The European Society of Intensive Care Medicine (ESICM) is organising the 24th ESICM LIVES Annual Congress in Berlin on 1-5 October 2011. This congress is one of the major meetings, gathering numerous well-known international experts in the field of intensive care medicine.
Location:Berlin
Organized by:European Society of Intensive Care Medicine
Clostridium difficile infection is the leading cause of healthcare-associated diarrhoea in the developed world and represents a major financial burden for European healthcare systems.
Clostridium difficile infection (CDI) is an intestinal infection usually acquired in hospital settings, after antibiotic treatment. The clinical spectrum of CDI ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis. In the recent years, an increased incidence of CDI has been reported in Europe and worldwide.
Starting 15 September 2011, ECDC will be coordinating the former EUVAC.NET network. It is a surveillance network covering measles, mumps, rubella, congenital rubella, pertussis and varicella EU Member States and three countries of the European Economic Area. Data will be hosted by the European Surveillance System (TESSy) at ECDC.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
On the occasion of World Hand Hygiene Day, 5th May, ECDC is releasing new web pages dedicated to the Healthcare-associated Infections Surveillance Network (HAI-Net) – a European network for HAI surveillance, coordinated by ECDC.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.